Protease nexin-1 expression is altered in human breast cancer
Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a...
Saved in:
Published in: | Cancer cell international Vol. 6; no. 1; p. 16 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
National Library of Medicine - MEDLINE Abstracts
31-05-2006
BioMed Central Ltd BioMed Central BMC |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this observation, we investigated if PN-1 is also expressed in human breast cancers where it may contribute to the regulation of uPA and participate in the development of a metastatic phenotype.
Using quantitative real-time PCR analysis, we measured PN-1 mRNA expression in tissues obtained from 26 human breast tumor biopsies and compared these values with those obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly correlates with the increased expression levels found for PAI-1 and uPA.
The fact that PN-1 expression is elevated in human breast cancer, and that its increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic spread. |
---|---|
AbstractList | Abstract Background Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this observation, we investigated if PN-1 is also expressed in human breast cancers where it may contribute to the regulation of uPA and participate in the development of a metastatic phenotype. Results Using quantitative real-time PCR analysis, we measured PN-1 mRNA expression in tissues obtained from 26 human breast tumor biopsies and compared these values with those obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly correlates with the increased expression levels found for PAI-1 and uPA. Conclusion The fact that PN-1 expression is elevated in human breast cancer, and that its increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic spread. BACKGROUNDUrokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this observation, we investigated if PN-1 is also expressed in human breast cancers where it may contribute to the regulation of uPA and participate in the development of a metastatic phenotype. RESULTSUsing quantitative real-time PCR analysis, we measured PN-1 mRNA expression in tissues obtained from 26 human breast tumor biopsies and compared these values with those obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly correlates with the increased expression levels found for PAI-1 and uPA. CONCLUSIONThe fact that PN-1 expression is elevated in human breast cancer, and that its increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic spread. BACKGROUND: Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this observation, we investigated if PN-1 is also expressed in human breast cancers where it may contribute to the regulation of uPA and participate in the development of a metastatic phenotype. RESULTS: Using quantitative real-time PCR analysis, we measured PN-1 mRNA expression in tissues obtained from 26 human breast tumor biopsies and compared these values with those obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly correlates with the increased expression levels found for PAI-1 and uPA. CONCLUSION: The fact that PN-1 expression is elevated in human breast cancer, and that its increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic spread. Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this observation, we investigated if PN-1 is also expressed in human breast cancers where it may contribute to the regulation of uPA and participate in the development of a metastatic phenotype. Using quantitative real-time PCR analysis, we measured PN-1 mRNA expression in tissues obtained from 26 human breast tumor biopsies and compared these values with those obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly correlates with the increased expression levels found for PAI-1 and uPA. The fact that PN-1 expression is elevated in human breast cancer, and that its increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic spread. |
ArticleNumber | 16 |
Author | Heaphy, Christopher M Hines, William C Candia, Britny J Orlando, Robert A Griffith, Jeffrey K |
AuthorAffiliation | 1 Department of Biochemistry and Molecular Biology, University of NewMexico, School of Medicine, MSC08 4670, 1 University of New Mexico, Albuquerque, New Mexico, 87131, USA |
AuthorAffiliation_xml | – name: 1 Department of Biochemistry and Molecular Biology, University of NewMexico, School of Medicine, MSC08 4670, 1 University of New Mexico, Albuquerque, New Mexico, 87131, USA |
Author_xml | – sequence: 1 givenname: Britny J surname: Candia fullname: Candia, Britny J email: bcandia@unm.edu organization: Department of Biochemistry and Molecular Biology, University of New Mexico, School of Medicine, MSC08 4670, Albuquerque, New Mexico 87131, USA. bcandia@unm.edu – sequence: 2 givenname: William C surname: Hines fullname: Hines, William C – sequence: 3 givenname: Christopher M surname: Heaphy fullname: Heaphy, Christopher M – sequence: 4 givenname: Jeffrey K surname: Griffith fullname: Griffith, Jeffrey K – sequence: 5 givenname: Robert A surname: Orlando fullname: Orlando, Robert A |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16737540$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kktv1DAQgC1URB9w5YgiDtxSPHZiOweQqopHpUpwgLPlx6T1KmsvdlKVf4-XXZUuiJOtmc-fRzNzSo5iikjIS6DnAEq8hU72LVNCtqIF8YScPASOHt2PyWkpK0pBKkGfkWMQksu-oyfk3decZjQFm4j3IbbQ4P0mYykhxSaUxkwzZvRNiM3tsjaxsbnSc-NMdJifk6ejmQq-2J9n5PvHD98uP7fXXz5dXV5ct7bnw9yCkhRHYTgoY0YLync991x6r1A57jtmkXPDR-axPpDWeT50ijnDqJWd5Gfkauf1yaz0Joe1yT91MkH_DqR8o02eg5tQD4gC7agsOuich6HnQCkbq0p4L1l1vd-5Notdo3cY52ymA-lhJoZbfZPuNPQUaD9UwcVOYEP6j-Aw49Jab0eht6PQQoOojjf7InL6sWCZ9ToUh9NkIqalaKEEE0zxCr7-C1ylJcfabM14Tweoc6zQ-Q5yOZWScXwoBqjersm_37963IM_-H4v-C_0Jbpt |
CitedBy_id | crossref_primary_10_1002_pmic_200700957 crossref_primary_10_2217_pgs_12_116 crossref_primary_10_1093_nar_gku814 crossref_primary_10_1155_2012_937506 crossref_primary_10_1016_j_semcdb_2016_08_012 crossref_primary_10_1038_s41419_019_1882_9 crossref_primary_10_1158_0008_5472_CAN_08_4573 crossref_primary_10_1038_srep37635 crossref_primary_10_1186_1471_2407_9_201 crossref_primary_10_1007_s11670_011_0092_5 crossref_primary_10_1007_s00432_014_1858_1 crossref_primary_10_1038_onc_2017_356 crossref_primary_10_1016_j_bbrc_2009_12_105 crossref_primary_10_1016_j_compbiomed_2023_107406 crossref_primary_10_1038_ctg_2014_2 crossref_primary_10_1515_hsz_2014_0254 crossref_primary_10_1016_j_oraloncology_2007_02_009 crossref_primary_10_1016_S2225_4110_16_30116_X crossref_primary_10_1016_j_bgm_2014_02_002 crossref_primary_10_1186_1477_7827_9_106 crossref_primary_10_1186_1476_4598_9_271 |
Cites_doi | 10.1055/s-0037-1616232 10.1016/0166-2236(88)90182-8 10.1016/0006-8993(86)90872-3 10.1159/000111951 10.1159/000055086 10.1055/s-0037-1615920 10.1159/000469153 10.1016/S0021-9258(17)32540-1 10.1016/S0021-9258(18)94159-1 10.2174/1381612043453559 10.1074/jbc.M310964200 10.1016/0092-8674(80)90112-9 10.1016/S0021-9258(18)53753-4 10.1055/s-2007-994920 10.1177/172460080001500113 10.1016/S0021-9258(17)44476-0 10.1016/S0049-3848(01)00288-2 10.1073/pnas.92.3.895 10.1111/j.1699-0463.1999.tb01534.x 10.1160/TH03-12-0784 10.1007/s000180050497 10.2174/1381612033454621 10.3109/10409239709082573 10.1093/clinchem/48.8.1288 10.1055/s-2007-999018 10.1016/0003-9861(87)90028-2 10.1038/bjc.1998.154 10.1002/jcp.1041170314 10.1023/A:1006115218786 10.1126/science.1067431 |
ContentType | Journal Article |
Copyright | Copyright National Library of Medicine - MEDLINE Abstracts 2006 Copyright © 2006 Candia et al; licensee BioMed Central Ltd. 2006 Candia et al; licensee BioMed Central Ltd. |
Copyright_xml | – notice: Copyright National Library of Medicine - MEDLINE Abstracts 2006 – notice: Copyright © 2006 Candia et al; licensee BioMed Central Ltd. 2006 Candia et al; licensee BioMed Central Ltd. |
DBID | NPM AAYXX CITATION K9. 7X8 5PM DOA |
DOI | 10.1186/1475-2867-6-16 |
DatabaseName | PubMed CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) PubMed |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1475-2867 |
EndPage | 16 |
ExternalDocumentID | oai_doaj_org_article_9ee6ebf8bec14cd19531002fa206dd72 oai_biomedcentral_com_1475_2867_6_16 1643942421 10_1186_1475_2867_6_16 16737540 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL063291 |
GroupedDBID | --- -56 -5G -A0 -BR 0R~ 29B 2VQ 2WC 4.4 53G 5GY 5VS 6J9 7X7 AAFWJ AAJSJ ABDBF ACGFO ACGFS ACIHN ACIWK ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BFQNJ BMC C1A C24 C6C CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FRP GROUPED_DOAJ GX1 H13 HYE IAO IHR IPNFZ ISR KQ8 M48 M~E NPM O5R O5S OK1 P2P PGMZT RBZ RIG RNS ROL RPM RSV SBL SOJ TR2 TUS W2D WOQ WOW XSB ~8M AAYXX CITATION K9. 7X8 ABVAZ AFGXO AFNRJ 5PM |
ID | FETCH-LOGICAL-b539t-1870ef6a318aafb18d453d37dd8e8c3d42be33a3f2de5397bcd39482ca20b7473 |
IEDL.DBID | RPM |
ISSN | 1475-2867 |
IngestDate | Tue Oct 22 15:05:25 EDT 2024 Tue Sep 17 21:24:58 EDT 2024 Wed May 22 07:13:16 EDT 2024 Fri Oct 25 01:26:34 EDT 2024 Thu Oct 10 15:52:50 EDT 2024 Thu Nov 21 21:55:05 EST 2024 Sat Sep 28 07:41:55 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b539t-1870ef6a318aafb18d453d37dd8e8c3d42be33a3f2de5397bcd39482ca20b7473 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1501059/ |
PMID | 16737540 |
PQID | 235091375 |
PQPubID | 42568 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_9ee6ebf8bec14cd19531002fa206dd72 pubmedcentral_primary_oai_pubmedcentral_nih_gov_1501059 biomedcentral_primary_oai_biomedcentral_com_1475_2867_6_16 proquest_miscellaneous_68626283 proquest_journals_235091375 crossref_primary_10_1186_1475_2867_6_16 pubmed_primary_16737540 |
PublicationCentury | 2000 |
PublicationDate | 2006-05-31 |
PublicationDateYYYYMMDD | 2006-05-31 |
PublicationDate_xml | – month: 05 year: 2006 text: 2006-05-31 day: 31 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Cancer cell international |
PublicationTitleAlternate | Cancer Cell Int |
PublicationYear | 2006 |
Publisher | National Library of Medicine - MEDLINE Abstracts BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: National Library of Medicine - MEDLINE Abstracts – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | 12004111 - Science. 2002 May 10;296(5570):1046-9 12142386 - Clin Chem. 2002 Aug;48(8):1288-95 3813534 - Arch Biochem Biophys. 1987 Jan;252(1):237-44 7846074 - Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):895-9 10066075 - Breast Cancer Res Treat. 1998;52(1-3):99-111 14754404 - Curr Pharm Des. 2004;10(1):39-49 11555589 - Clin Cancer Res. 2001 Sep;7(9):2757-64 1884381 - Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-5059s 11457471 - Thromb Res. 2001 Jul 15;103(2):135-42 10763144 - Int J Biol Markers. 2000 Jan-Mar;15(1):70-2 14983218 - Thromb Haemost. 2004 Mar;91(3):438-49 3730865 - Brain Res. 1986 Jul 9;377(2):298-304 2521625 - J Biol Chem. 1989 Feb 5;264(4):2185-8 3771529 - J Biol Chem. 1986 Oct 25;261(30):14184-90 8006028 - J Biol Chem. 1994 Jun 24;269(25):17199-205 11487024 - Thromb Haemost. 2001 Jul;86(1):346-55 3139400 - Enzyme. 1988;40(2-3):113-21 10605712 - Thromb Haemost. 1999 Aug;82(2):259-70 8429047 - J Biol Chem. 1993 Feb 15;268(5):3720-7 6157479 - Cell. 1980 Aug;21(1):37-45 8836012 - Semin Thromb Hemost. 1996;22(3):267-71 6317700 - J Cell Physiol. 1983 Dec;117(3):385-96 9239493 - Crit Rev Biochem Mol Biol. 1997;32(3):175-253 15138609 - Int J Mol Med. 2004 Jun;13(6):759-66 3371230 - Dev Neurosci. 1988;10(1):17-24 12871067 - Curr Pharm Des. 2003;9(19):1545-64 9528837 - Br J Cancer. 1998 Mar;77(6):932-40 10357086 - Semin Thromb Hemost. 1999;25(2):183-97 1288365 - Ann N Y Acad Sci. 1992 Dec 31;674:228-36 12941819 - Cancer Res. 2003 Aug 15;63(16):4945-51 6885787 - J Biol Chem. 1983 Sep 10;258(17):10439-44 11455216 - Onkologie. 2001 Jun;24(3):238-44 14699093 - J Biol Chem. 2004 Mar 12;279(11):10346-56 14758095 - Breast Cancer Res Treat. 2004 Feb;83(3):249-89 10190288 - APMIS. 1999 Jan;107(1):120-7 2471310 - Trends Neurosci. 1988 Dec;11(12):541-4 10949579 - Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 JT Price (152_CR1) 1997; 32 PJ Vaughan (152_CR15) 1993; 268 MP Look (152_CR26) 2000; 15 AD Zurn (152_CR17) 1988; 10 RW Stephens (152_CR9) 1998; 52 MK Durand (152_CR28) 2004; 91 DD Cunningham (152_CR33) 1992 A Knoop (152_CR8) 1998; 77 EW Howard (152_CR22) 1986 D Monard (152_CR34) 1988; 11 NK Kim (152_CR12) 2001; 103 (2) N Harbeck (152_CR24) 2001; 7 SR Stone (152_CR14) 1987; 252 V Ellis (152_CR5) 1989; 264 RWBJB Scott (152_CR23) 1983; 258 K Dano (152_CR2) 1999; 107 P Rossignol (152_CR35) 2004; 279 FM Donovan (152_CR20) 1994; 269 JB Baker (152_CR37) 1980; 21 BS Wiseman (152_CR36) 2002; 296 LA Liotta (152_CR7) 1991; 51 MJ Duffy (152_CR30) 2004; 10(1) J Chorostowska-Wynimko (152_CR32) 2004; 13(6) VA Carroll (152_CR3) 1999; 25 EK Kruithof (152_CR13) 1988; 40 S Stefansson (152_CR29) 2003; 9 PA Andreasen (152_CR4) 2000; 57 MLG Lacroix (152_CR27) 2004 D Collen (152_CR10) 1999; 82 R Castello (152_CR21) 2002; 48 M Buchholz (152_CR31) 2003; 63 BW Festoff (152_CR18) 1996; 22 MS Pepper (152_CR6) 2001; 86 J Lindner (152_CR19) 1986; 377 DJ Knauer (152_CR11) 1983; 117 LJ Houenou (152_CR16) 1995; 92 N Harbeck (152_CR25) 2001; 24 |
References_xml | – volume: 86 start-page: 346 year: 2001 ident: 152_CR6 publication-title: Thrombosis & Haemostasis doi: 10.1055/s-0037-1616232 contributor: fullname: MS Pepper – volume: 11 start-page: 541 issue: 12 year: 1988 ident: 152_CR34 publication-title: Trends in neurosciences doi: 10.1016/0166-2236(88)90182-8 contributor: fullname: D Monard – start-page: 249 volume-title: Breast Cancer Research and Treatment year: 2004 ident: 152_CR27 contributor: fullname: MLG Lacroix – volume: 377 start-page: 298 issue: 2 year: 1986 ident: 152_CR19 publication-title: Brain Research doi: 10.1016/0006-8993(86)90872-3 contributor: fullname: J Lindner – volume: 10 start-page: 17 issue: 1 year: 1988 ident: 152_CR17 publication-title: Developmental Neuroscience doi: 10.1159/000111951 contributor: fullname: AD Zurn – volume: 24 start-page: 238 issue: 3 year: 2001 ident: 152_CR25 publication-title: Onkologie doi: 10.1159/000055086 contributor: fullname: N Harbeck – volume: 82 start-page: 259 year: 1999 ident: 152_CR10 publication-title: Thrombosis & Haemostasis doi: 10.1055/s-0037-1615920 contributor: fullname: D Collen – volume: 40 start-page: 113 issue: 2-3 year: 1988 ident: 152_CR13 publication-title: Enzyme doi: 10.1159/000469153 contributor: fullname: EK Kruithof – volume: 269 start-page: 17199 issue: 25 year: 1994 ident: 152_CR20 publication-title: Journal of Biological Chemistry doi: 10.1016/S0021-9258(17)32540-1 contributor: fullname: FM Donovan – volume: 264 start-page: 2185 issue: 4 year: 1989 ident: 152_CR5 publication-title: Journal of Biological Chemistry doi: 10.1016/S0021-9258(18)94159-1 contributor: fullname: V Ellis – start-page: 14184 volume-title: Journal of Biological Chemistry year: 1986 ident: 152_CR22 contributor: fullname: EW Howard – volume: 10(1) start-page: 39 year: 2004 ident: 152_CR30 publication-title: Current pharmaceutical design doi: 10.2174/1381612043453559 contributor: fullname: MJ Duffy – volume: 279 start-page: 10346 issue: 11 year: 2004 ident: 152_CR35 publication-title: J Biol Chem doi: 10.1074/jbc.M310964200 contributor: fullname: P Rossignol – volume: 21 start-page: 37 issue: 1 year: 1980 ident: 152_CR37 publication-title: Cell doi: 10.1016/0092-8674(80)90112-9 contributor: fullname: JB Baker – volume: 268 start-page: 3720 issue: 5 year: 1993 ident: 152_CR15 publication-title: Journal of Biological Chemistry doi: 10.1016/S0021-9258(18)53753-4 contributor: fullname: PJ Vaughan – volume: 7 start-page: 2757 issue: 9 year: 2001 ident: 152_CR24 publication-title: Clinical Cancer Research contributor: fullname: N Harbeck – volume: 25 start-page: 183 issue: 2 year: 1999 ident: 152_CR3 publication-title: Seminars in Thrombosis & Hemostasis doi: 10.1055/s-2007-994920 contributor: fullname: VA Carroll – volume: 15 start-page: 70 issue: 1 year: 2000 ident: 152_CR26 publication-title: International Journal of Biological Markers doi: 10.1177/172460080001500113 contributor: fullname: MP Look – volume: 258 start-page: 10439 year: 1983 ident: 152_CR23 publication-title: Journal of Biological Chemistry doi: 10.1016/S0021-9258(17)44476-0 contributor: fullname: RWBJB Scott – volume: 103 (2) start-page: 135 year: 2001 ident: 152_CR12 publication-title: Thrombosis Research doi: 10.1016/S0049-3848(01)00288-2 contributor: fullname: NK Kim – volume: 92 start-page: 895 issue: 3 year: 1995 ident: 152_CR16 publication-title: Proceedings of the National Academy of Sciences of the United States of America doi: 10.1073/pnas.92.3.895 contributor: fullname: LJ Houenou – volume: 107 start-page: 120 issue: 1 year: 1999 ident: 152_CR2 publication-title: APMIS doi: 10.1111/j.1699-0463.1999.tb01534.x contributor: fullname: K Dano – volume: 51 start-page: 5054s issue: 18 Suppl year: 1991 ident: 152_CR7 publication-title: Cancer Research contributor: fullname: LA Liotta – start-page: 228 volume-title: Annals of the New York Academy of Sciences year: 1992 ident: 152_CR33 contributor: fullname: DD Cunningham – volume: 91 start-page: 438 issue: 3 year: 2004 ident: 152_CR28 publication-title: Thromb Haemost doi: 10.1160/TH03-12-0784 contributor: fullname: MK Durand – volume: 13(6) start-page: 759 year: 2004 ident: 152_CR32 publication-title: International journal of molecular medicine contributor: fullname: J Chorostowska-Wynimko – volume: 57 start-page: 25 issue: 1 year: 2000 ident: 152_CR4 publication-title: Cellular & Molecular Life Sciences doi: 10.1007/s000180050497 contributor: fullname: PA Andreasen – volume: 9 start-page: 1545 issue: 19 year: 2003 ident: 152_CR29 publication-title: Curr Pharm Des doi: 10.2174/1381612033454621 contributor: fullname: S Stefansson – volume: 32 start-page: 175 issue: 3 year: 1997 ident: 152_CR1 publication-title: Critical Reviews in Biochemistry & Molecular Biology doi: 10.3109/10409239709082573 contributor: fullname: JT Price – volume: 63 start-page: 4945 issue: 16 year: 2003 ident: 152_CR31 publication-title: Cancer Research contributor: fullname: M Buchholz – volume: 48 start-page: 1288 issue: 8 year: 2002 ident: 152_CR21 publication-title: Clinical Chemistry doi: 10.1093/clinchem/48.8.1288 contributor: fullname: R Castello – volume: 22 start-page: 267 issue: 3 year: 1996 ident: 152_CR18 publication-title: Seminars in Thrombosis & Hemostasis doi: 10.1055/s-2007-999018 contributor: fullname: BW Festoff – volume: 252 start-page: 237 issue: 1 year: 1987 ident: 152_CR14 publication-title: Archives of Biochemistry & Biophysics doi: 10.1016/0003-9861(87)90028-2 contributor: fullname: SR Stone – volume: 77 start-page: 932 issue: 6 year: 1998 ident: 152_CR8 publication-title: British Journal of Cancer doi: 10.1038/bjc.1998.154 contributor: fullname: A Knoop – volume: 117 start-page: 385 issue: 3 year: 1983 ident: 152_CR11 publication-title: J Cell Physiol doi: 10.1002/jcp.1041170314 contributor: fullname: DJ Knauer – volume: 52 start-page: 99 issue: 1-3 year: 1998 ident: 152_CR9 publication-title: Breast Cancer Research & Treatment doi: 10.1023/A:1006115218786 contributor: fullname: RW Stephens – volume: 296 start-page: 1046 issue: 5570 year: 2002 ident: 152_CR36 publication-title: Science doi: 10.1126/science.1067431 contributor: fullname: BS Wiseman |
SSID | ssj0017860 |
Score | 1.8800023 |
Snippet | Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of... BACKGROUND: Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation... BACKGROUNDUrokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of... Abstract Background Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the... |
SourceID | doaj pubmedcentral biomedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 16 |
SubjectTerms | Breast cancer Primary Research |
SummonAdditionalLinks | – databaseName: BiomedCentral dbid: RBZ link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB0VqkpcSqHQBij4UAkuUdexYzvcoAVx4gBUQlwsJ-OoK1WhYnel9t93JskuBDggcY3jyJkP-Y1n_AbgqybUHZBp9gkTpUx4l7qCjzkqW7usouG2N-DZpT2_dj9OmCbn4PkMvnTmm9Q2TzNH_mxSaZbgLQUMmm354vhmkS-wrrsPPH-3p2d8Ov_Rvfbfg-2oZe1_Dmo-rph8sAWdrr588R_gfQ8zxVFnF2vwJjbr8K5rPPnvIzBJ_pQTM4KpMJtUivi3r4htxHgi2hx6RDFuRNvET5Rcuz4VFdvI3Qb8PD25-n6W9o0U0jJXxZT0YEexNoH8N4S6lA51rlBZRBddpVBnZVQqqDrDSBNsWaEqNKkqZKOS4g21CcvNbRM_gxi5skYstDWy1hJDMcop4imCxTxQLBkTOBzI1__pSDM801gPR8ijPMvHs3y88dIksD9XxmJeG6Q48-TNY9bV4OvtAxK-733OFzGaWNaOzFTqCjlhyISzNf2VQbRZAttzTfvecyc-UwyhlM0T2FuMkstxHiU08XY28XypxhAsS-BTZxX3i-WuP4SBE7ADexmsczjSjH-1pN4EzBnqbr1Gftuw0p0QcXHDDixP72bxCyxNcLbbust_zgkPIg priority: 500 providerName: BioMedCentral – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwEB3RlZC4VLR8hQXqAxKnaJM4sR1uFHa1Jy6AxM1yMo5YqUqrJivRf89MnA2kReqlVztOnPFM_CYzfgPwPifU7ZBp9gkTxUx4F5uSf3PUujFZTd1DbcDtN_31p_myZpqcqdQX54QFeuAguFXpvfJVY-hZaV4jR32YNbRxWaIQdfj6JurgTI3xA23C-eBcF3FmlB7pGlOjVlNbrGKucj47534x254GFv__Qc_bGZT_bEmbp3A8YknxKbzDCTzy7Sk8DtUlb54BM-H3HH0RzHfZxqnwv8e011bsOjEEyj2KXSuGSn2i4gT1XtSsCNfP4cdm_f3zNh6rJcRVIcuehK0T3yhHRupcU6UG80Ki1IjGm1pinlVeSiebDD0N0FWNssxpPUiSFTkV8gUs2svWvwKRmKpBLHOt0iZP0ZVJQW5N6TQWjhxGH8HHmdDsVWDGsMxVPe8hs7EsccsSt8qmKoIPBwlP4wZPxKg7V57zAszuPjSQfthRP-x9-hHB8rB8djTPzmaScZLURQRnUy_ZFQdLXOsv953lkzOKsFcEL8NS_50sl_YhoBuBninBbJ7znnb3a2DuJvTNePb1Q7zYEp6E30GcyfAGFv313r-Fow737wZb-AMEXA0b priority: 102 providerName: Directory of Open Access Journals |
Title | Protease nexin-1 expression is altered in human breast cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/16737540 https://www.proquest.com/docview/235091375 https://search.proquest.com/docview/68626283 http://dx.doi.org/10.1186/1475-2867-6-16 https://pubmed.ncbi.nlm.nih.gov/PMC1501059 https://doaj.org/article/9ee6ebf8bec14cd19531002fa206dd72 |
Volume | 6 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6xlZC4ICivUGh9QOKUbhwntsONvtRLEeIhIS6WHTt0pTZb7UOCf8-M4xQCnLjkEMeRM56Jv_GMvwF4VSHqtp5o9hET5UR4l-uGtjla1emyxeZYG_D8o3r3RZ-cEk1OPZ6FiUn7rVsc9lfXh_3iMuZW3ly38zFPbP7-4hhBDMGC-QxmiA1HFz2FDpSWRWJn5FrOeaXqvNT4O5A5jwWLqDJL3OyYnHC_mixMkb__X6Dzz9zJ3xajswdwP6FI9nYY7UO4E_pduDvUlfzxCIgDf0NxF0ZMl33OWfieEl57tlizGCIPni16Fmv0MUep6RvWkgqsHsPns9NPx-d5qpOQu1o0GxSzKkInLZqntZ3j2le18EJ5r4Nuha9KF4Swoit9wA7KtV40Fc6ELQuH7oR4Ajv9sg_PgBXadd43lZK8q7i3TVGjQ9NY5WuLrmLI4M1EaOZm4MQwxFI9bUGDMSR8Q8I30nCZwetRwrf9og-i5V9PHtEETN4ebyxX30zSBNOEIIPrNGohr1pP8UDik-3wq6T3qsxgb5w-kwxzbUpBCAkVIIOD21a0KAqT2D4st2tDZ2Ykoq4Mng5T_WuwSXUyUBMlmIxz2oIqHDm7k8o-_--ee3Bv2P2hxIUXsLNZbcNLmK39dj_uI-D1w9HX_WgLPwHnaAzc |
link.rule.ids | 108,230,315,729,782,786,866,887,2106,24946,27933,27934,53800,53802,75821,75822 |
linkProvider | National Library of Medicine |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9UwDLfYEIIL45uywXJA4tS9pmmTlBsbmx5im5AYErcobdLxpC1veh8S_PfYaTtW4LRr3VRpbLc_x87PAG8LRN3WEc0-YqKUCO9SXdE2R6NanTcojr0Bp1_V6Xf98ZBocsrhLEws2m_q2V64uNwLsx-xtvLqspkMdWKTLycHCGIIFkw24C76a5YNQXqfPFBaZj0_I9dywgtVprnGD4JMeWxZRL1Z4nbH6Iz7xejXFBn8_wc7_66evPE7Otq65Ys8goc9_mQfOvFjuOPDE7jXdaT89RSIPX9FGRtGHJkh5cz_7EtlA5stWUyue8dmgcXufqymovYVa8h4Fs_g29Hh2cE07TsspHUpqhUqSGW-lRYd29q25toVpXBCOae9boQr8toLYUWbO48DVN04URWoQ5tnNQYi4jlshnnwL4Flum6dqwoleVtwZ6usxFCossqVFoNMn8D70WKbq45NwxC_9ViCrmZIaYaUZqThMoF3g2aux8XoRct_7twnxY2eHi_MF-emX3pTeS993Wq0X140jjKJxETb4ltJ51SewPagdtO79NLkgrAVGk4Cu9dS9EVKsNjg5-ulodM2EvFaAi86E_kz2d7kElAj4xnNcyxBm4ls372NvLr1yF24Pz07OTbHn04_b8ODbg-Jyh92YHO1WPvXsLF06zfRh34Ded8gVQ |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RIlAvvKGhQH1A4pQmjhPb4QZtV0VAVQmQuFl27MBKbXa1Dwn-PTNOdiHACa6xHTmemfgbz_gbgOclom7riWYfMVFKhHeprumYo1GtLhpsjrUBzz6o88_65JRocralvmLSfuOmR93l1VE3_RpzK-dXTbbJE8su3h8jiCFYkM19m-3AdbTZvNg46kMAQWmZDxyNXMuMl6pKC40_BZnyWLaI6rPEI4_RPffL0fYUWfz_Bj1_z6D8ZUua3P6Pj7kDtwYcyl71Xe7CtdDdgxt9Zcrv94FY9FcUuWHEldmlnIVvQ8psx6ZLFoPswbNpx2KVP-YouX3FGlKixQP4NDn9eHyWDpUWUleJeoWCUnlopUUDt7Z1XPuyEl4o73XQjfBl4YIQVrSFDzhAucaLukRZ2iJ36JCIh7DbzbqwDyzXrvW-LpXkbcm9rfMKXaLaKl9ZdDZDAi9HC27mPauGIZ7rcQuanCHBGRKckYbLBF5spLMdF70YLf_o-ZqEN3p7fDBbfDHD8ps6BBlcq1GPedl4iigSI22LXyW9V0UCBxvRm8G0l6YQhLFQeRI43LaiTVKgxXZhtl4aunUjEbcl8KhXk5-THdQuATVSoNE8xy2oN5H1e9CTx_888hBuXpxMzLs3528PYK8_SqIsiCewu1qsw1PYWfr1s2hGPwB83SLV |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protease+nexin-1+expression+is+altered+in+human+breast+cancer&rft.jtitle=Cancer+cell+international&rft.au=Candia%2C+Britny+J&rft.au=Hines%2C+William+C&rft.au=Heaphy%2C+Christopher+M&rft.au=Griffith%2C+Jeffrey+K&rft.date=2006-05-31&rft.pub=National+Library+of+Medicine+-+MEDLINE+Abstracts&rft.eissn=1475-2867&rft.volume=6&rft.spage=16&rft_id=info:doi/10.1186%2F1475-2867-6-16&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=1643942421 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2867&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2867&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2867&client=summon |